2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Journal of Hypertension, Год журнала: 2023, Номер 41(12), С. 1874 - 2071

Опубликована: Июнь 24, 2023

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).

Язык: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Circulation, Год журнала: 2023, Номер 148(9)

Опубликована: Июль 20, 2023

AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Diagnosis Stable Ischemic Heart corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update Disease.” METHODS: A comprehensive literature search was conducted from September 2021 May 2022. Clinical studies, systematic reviews meta-analyses, other on human participants were identified that published in English MEDLINE (through PubMed), EMBASE, Cochrane Library, Agency Healthcare Research Quality, selected databases relevant this guideline. STRUCTURE: This guideline evidenced-based patient-centered approach management patients with chronic coronary disease, considering social determinants health incorporating principles shared decision-making team-based care. Relevant topics include general approaches treatment decisions, guideline-directed therapy reduce symptoms future cardiovascular events, pertaining revascularization recommendations special populations, patient follow-up monitoring, gaps, areas need research. Where applicable, based availability cost-effectiveness data, cost–value are also provided clinicians. Many previously guidelines have been updated evidence, created when supported by data.

Язык: Английский

---

2024 ESC Guidelines for the management of chronic coronary syndromes

European Heart Journal, Год журнала: 2024, Номер 45(36), С. 3415 - 3537

Опубликована: Авг. 30, 2024

Язык: Английский

---

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Nature Medicine, Год журнала: 2022, Номер 28(10), С. 2083 - 2091

Опубликована: Окт. 1, 2022

Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment adults with obesity, or overweight at least one weight-related comorbidity, without diabetes. co-primary endpoints were percentage change in body weight achievement loss ≥5% week 104. Efficacy was among all randomized participants regardless discontinuation rescue intervention. From October 2018 to 1 February 2019, 304 randomly assigned ( n = 152) 152), 92.8% whom completed (attended end-of-trial visit). Most female (236 (77.6%)) white (283 (93.1%)), a mean (s.d.) age 47.3 (11.0) years, mass index 38.5 (6.9) kg m –2 106.0 (22.0) kg. from baseline 104 −15.2% group −2.6% an estimated difference −12.6 %-points (95% confidence interval, −15.3 −9.8; P < 0.0001). More than achieved (77.1% 34.4%; Gastrointestinal adverse events, mostly mild-to-moderate, reported more often (82.2% 53.9%). In summary, (with comorbidity) led substantial, sustained over weeks placebo. NCT03693430

Язык: Английский

---

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

EClinicalMedicine, Год журнала: 2023, Номер 58, С. 101882 - 101882

Опубликована: Март 21, 2023

Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for treatment excess recent advances have revolutionized how we treat, more importantly will be treating obesity in near future. Metreleptin Setmelanotide are currently indicated rare syndromes, 5 other medications (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) approved non-syndromic obesity. Tirzepatide about to approved, drugs, with exciting novel mechanisms action primarily based on incretins, being investigated different phases clinical trials. The majority these compounds act centrally, reduce appetite increase satiety, secondarily, gastrointestinal tract slow gastric emptying. All anti-obesity improve metabolic parameters, variable potency effects depending specific drug. available data do not support reduction hard cardiovascular outcomes, but it almost certain that such forthcoming very choice medication needs take into consideration patient's biochemical profile, co-morbidities, drug contra-indications, as well expected degree loss improvements cardio-renal risk. It also seen whether precision medicine may offer personalized solutions individuals obesity, represent future medical along development novel, potent, pipeline.FundingNone.

Язык: Английский

---

Signaling pathways in obesity: mechanisms and therapeutic interventions

Signal Transduction and Targeted Therapy, Год журнала: 2022, Номер 7(1)

Опубликована: Авг. 28, 2022

Abstract Obesity is a complex, chronic disease and global public health challenge. Characterized by excessive fat accumulation in the body, obesity sharply increases risk of several diseases, such as type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver linked to lower life expectancy. Although lifestyle intervention (diet exercise) has remarkable effects on weight management, achieving long-term success at loss extremely challenging, prevalence continues rise worldwide. Over past decades, pathophysiology been extensively investigated, an increasing number signal transduction pathways have implicated obesity, making it possible fight more effective precise way. In this review, we summarize recent advances pathogenesis from both experimental clinical studies, focusing signaling their roles regulation food intake, glucose homeostasis, adipogenesis, thermogenesis, inflammation. We also discuss current anti-obesity drugs, well compounds trials, that target these signals. The evolving knowledge may shed light future direction research, move into new era precision medicine.

Язык: Английский

---

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

JAMA, Год журнала: 2023, Номер 330(18), С. 1795 - 1795

Опубликована: Окт. 5, 2023

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Язык: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease

Journal of the American College of Cardiology, Год журнала: 2023, Номер 82(9), С. 833 - 955

Опубликована: Июль 20, 2023

Язык: Английский

---

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity

Gastroenterology, Год журнала: 2022, Номер 163(5), С. 1198 - 1225

Опубликована: Окт. 20, 2022

Язык: Английский

---

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

JAMA Network Open, Год журнала: 2022, Номер 5(9), С. e2231982 - e2231982

Опубликована: Сен. 19, 2022

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To weight loss outcomes associated with treatment for patients overweight or obesity. Design, Setting, Participants This study, conducted a referral center management, retrospectively collected data on use adults between January 1, 2021, March 15, 2022, follow-up up 6 months. A total 408 body mass index (BMI) 27 more were prescribed weekly subcutaneous injections 3 months more. Patients history bariatric procedures, taking other antiobesity medications, an active malignant neoplasm excluded. Exposures Weekly 1.7-mg 2.4-mg Main Outcomes Measures The primary end point was percentage loss. Secondary points proportion achieving 5% more, 10% 15% 20% after without type 2 diabetes Results included 175 (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; BMI, 41.3 [9.1]) analysis 102 (SD) 6.7 (4.4) kg, equivalent 5.9% (3.7%) ( P &lt; .001), 12.3 (6.6) 10.9% (5.8%) .001 from baseline). Of who followed months, 89 (87.3%) achieved 56 (54.9%) 24 (23.5%) 8 (7.8%) had lower compared those diabetes: 3.9% (3.1%) vs 6.3% = .001) 7.2% (6.3%) 11.8% (5.3%) .005). Conclusions Relevance results this suggest that similar seen trials. Studies longer periods are needed evaluate prolonged outcomes.

Язык: Английский

---